Latest Organofluorides Stories
The Firm is actively filing Risperdal lawsuits in this proceeding on behalf of men and young boys who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic
FORT WORTH, Texas, November 26, 2014 /PRNewswire/ -- The global fluoropolymer coating additives market report defines and segments the coating additives market to provide
RnRMarketResearch.com adds “Market Research Report on Global and Chinese Olaparib (CAS 763113-22-0) Industry, 2009-2019” Latest Report to its store. Dallas,
BURNABY, Canada, November 24, 2014 /PRNewswire/ -- Rising Demand for Chemically Inert Material in Chemical and Industrial Processing Would Continue to Boost Fluoropolymers
Study Addresses Key Question Raised in Regulatory Review; Flibanserin New Drug Application to be Resubmitted Q1 2015 RALEIGH, N.C., Nov.
The Firm is evaluating Lipitor lawsuits on behalf of patients who developed Type 2 diabetes, allegedly due to their use of the statin medication. New York, New
First Long-Acting Treatment to be Used Four Times a Year for Schizophrenia in Adults TITUSVILLE, N.J., Nov.
All six trials met primary efficacy endpoint TARRYTOWN, N.Y. and PARIS, Nov. 19, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
- All six trials met primary efficacy endpoint - PARIS AND TARRYTOWN, N.Y., Nov. 19, 2014 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc.
The Firm is representing numerous Risperdal lawsuit clients who allegedly developed gynecomastia (male breast growth) due to their use of the atypical antipsychotic medication. (PRWEB)